These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 17478466

  • 1. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F.
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J.
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A.
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [Abstract] [Full Text] [Related]

  • 4. Infliximab in the treatment of refractory posterior uveitis.
    Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ.
    Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
    [Abstract] [Full Text] [Related]

  • 5. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R, Loza E, Jover JA, Benitez Del Castillo JM, Mendez R, Hernandez-Garcia C, Pato E.
    Scand J Rheumatol; 2009 Jul; 38(1):58-62. PubMed ID: 18991187
    [Abstract] [Full Text] [Related]

  • 6. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S, Graziani G, Marcolongo R.
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [Abstract] [Full Text] [Related]

  • 7. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC, Iannone F, Scioscia C, Grattagliano V, Covelli M, Lapadula G.
    Reumatismo; 2004 Sep; 56(3):185-9. PubMed ID: 15470524
    [Abstract] [Full Text] [Related]

  • 8. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF, Al-Hemidan AI.
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [Abstract] [Full Text] [Related]

  • 9. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G.
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M.
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [Abstract] [Full Text] [Related]

  • 12. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H, Okada AA, Watanabe T, Taki W.
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [Abstract] [Full Text] [Related]

  • 13. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D.
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A.
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [Abstract] [Full Text] [Related]

  • 15. Azathioprine in severe uveitis of Behçet's disease.
    Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, Cassoux N, Le Hoang P, Amoura Z, Bodaghi B, Cacoub P.
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1733-8. PubMed ID: 20665749
    [Abstract] [Full Text] [Related]

  • 16. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
    Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M.
    Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
    [Abstract] [Full Text] [Related]

  • 17. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM.
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [Abstract] [Full Text] [Related]

  • 18. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [Abstract] [Full Text] [Related]

  • 19. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.
    Jpn J Ophthalmol; 2007 Nov; 51(3):191-6. PubMed ID: 17554481
    [Abstract] [Full Text] [Related]

  • 20. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
    Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, Cimaz R.
    Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.